Related Experiment Videos
Interstitial laser coagulation for benign prostatic hyperplasia: preliminary clinical results
1Department of Urology, Kurashiki Central Hospital, Japan.
Summary
Interstitial laser coagulation of the prostate (ILCP) offers a safe and effective treatment for benign prostatic hyperplasia (BPH). This minimally invasive procedure significantly improves urinary symptoms and quality of life for patients.
Area of Science:
- Urology
- Minimally Invasive Surgery
- Laser Therapeutics
Background:
- Benign prostatic hyperplasia (BPH) is a common condition affecting aging men.
- Current BPH treatments vary in efficacy and invasiveness.
- Interstitial laser coagulation of the prostate (ILCP) presents a novel therapeutic approach.
Purpose of the Study:
- To evaluate the early clinical experience and outcomes of ILCP for BPH treatment.
- To assess the safety and efficacy of ILCP in a patient cohort.
Main Methods:
- 37 symptomatic BPH patients underwent ILCP using Neodymium: YAG laser energy.
- Laser energy was delivered via transurethrally inserted interstitial thermotherapy light guides.
- Prostatic urethra preservation was a key procedural aspect.
Main Results:
- Significant improvements observed in International Prostatic Symptom Score (I-PSS) and peak flow rate at 3 months (p < 0.0001).
- Mean postvoided residual urine volume decreased significantly (p < 0.01).
- Quality of life scores improved significantly (p < 0.0001), with no serious side-effects reported.
Conclusions:
- ILCP demonstrates early promise as a safe and effective minimally invasive treatment for BPH.
- The procedure preserves the prostatic urethra, potentially reducing complications.
- Further studies are warranted to confirm long-term outcomes.